Liu Yueying, Ni Hong, Wang Chunhong, Li Lili, Cheng Zaohuo, Weng Zhen
1 Department of Pediatrics, Affiliated Hospital, Jiangnan University , Wuxi, Jiangsu, China .
2 Neurology Laboratory, Soochow University Affiliated Children's Hospital , Suzhou, Jiangsu, China .
J Child Adolesc Psychopharmacol. 2016 Jun;26(5):436-41. doi: 10.1089/cap.2015.0125. Epub 2016 Feb 25.
Aripiprazole, an atypical antipsychotic drug, has shown potential as a promising candidate for the treatment of Tourette's disorder (TD). However, the effectiveness and the tolerability profile of aripiprazole in the reduction of tics in children and adolescents with TD have not been systematically analyzed. This meta-analysis aimed to evaluate the effectiveness and tolerability of aripiprazole in children and adolescents with TD.
We searched for clinical trials that investigated the effect of aripiprazole in children and adolescents with TD in PubMed and Web of Science. The outcomes of interest comprised the Yale Global Tic Severity Score (YGTSS) total tic scores and the Clinical Global Impressions Scale for Tic Severity (CGI-S) scores. The pooled effect size (ES) and 95% confidence interval (CI) were calculated to assess the effectiveness of aripiprazole in children and adolescents with TD.
Ten studies were retrieved from 122 citations for the analysis, and in total, 302 patients (mean age, 11.6 years; median follow-up, 9 weeks) were included in the analysis. After synthesis of the data, the meta-analysis showed significantly greater improvement in the mean change in the YGTSS total tic scores (ES = -1.99, 95% CI = [-2.26]-[-1.72]; p = 0.001) and the mean CGI-S scores (ES = -2.34, 95% CI = [-2.96]-[-1.73]; p = 0.001) from pretreatment to posttreatment. Adverse events were reported in nine trials. Drowsiness (28.5%), nausea (20.2%), and headache (13.8%) were common adverse events.
The use of aripiprazole is safe, and shows therapeutic effectiveness in children and adolescents with TD.
阿立哌唑是一种非典型抗精神病药物，已显示出作为治疗抽动秽语综合征（TD）的有前景候选药物的潜力。然而，阿立哌唑在减少TD儿童和青少年抽动方面的有效性和耐受性尚未得到系统分析。本荟萃分析旨在评估阿立哌唑在TD儿童和青少年中的有效性和耐受性。
我们在PubMed和科学网中搜索了研究阿立哌唑对TD儿童和青少年影响的临床试验。感兴趣的结果包括耶鲁全球抽动严重程度评分（YGTSS）总抽动分数和抽动严重程度临床总体印象量表（CGI-S）评分。计算合并效应量（ES）和95%置信区间（CI）以评估阿立哌唑在TD儿童和青少年中的有效性。
从122篇文献中检索出10项研究进行分析，总计302例患者（平均年龄11.6岁；中位随访9周）纳入分析。数据综合后，荟萃分析显示从治疗前到治疗后，YGTSS总抽动分数的平均变化（ES = -1.99，95%CI = [-2.26]-[-1.72]；p = 0.001）和平均CGI-S评分（ES = -2.34，95%CI = [-2.96]-[-1.73]；p = 0.001）有显著更大改善。9项试验报告了不良事件。嗜睡（28.5%）、恶心（20.2%）和头痛（13.8%）是常见不良事件。
阿立哌唑的使用是安全的，并且在TD儿童和青少年中显示出治疗效果。
